| Status: Recommended | |||
Etravirine (Intelence®) is recommended as an option for use within NHS Wales, in combination with a boosted protease inhibitor and other antiretroviral medicinal products, for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced adults and in antiretroviral treatment-experienced paediatric patients from 2 years of age. |
|||
|
|||
Medicine details |
|||
| Medicine name | etravirine (Intelence®) | ||
| Formulation | 25 mg, 100 mg, 200 mg tablets | ||
| Reference number | 4506 | ||
| Indication | In combination with a boosted protease inhibitor and other antiretroviral medicinal products, for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced adults and in antiretroviral treatment-experienced paediatric patients from 2 years of age |
||
| Company | Janssen-Cilag Ltd | ||
| BNF chapter | Infections | ||
| Submission type | Licence extension for paediatric use | ||
| Status | Recommended | ||
| Advice number | 1421 | ||
| AWMSG meeting date | 14/09/2021 | ||
| Date of issue | 30/09/2021 | ||
| Further information This advice incorporates and replaces the AWMSG recommendation for etravirine (Intelence®) for use in combination with a boosted protease inhibitor and other antiretroviral medicinal products, for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced paediatric patients from 6 years to less than 18 years of age (advice number 3213, originally published December 2013) and the AWMSG recommendation for etravirine (Intelence®) for the treatment of HIV-1 infected, antiretroviral treatment-experienced adults in combination with a boosted protease inhibitor and other antiretroviral medicinal products (advice number 0609, originally published September 2009). |
|||